Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: A method for producing, without a mold, a shaped glass article having a predefined geometry is provided. The method includes providing a starting glass, supporting the starting glass, heating a portion of the starting glass so that in the portion a predetermined spatial viscosity distribution of the starting glass is obtained from 109 to 104 dPa·s and so that at points where the starting glass is supported a predetermined spatial viscosity distribution of the starting glass does not fall below 1013 dPa·s, and deforming the heated starting glass by action of an external force until the predefined geometry of the glass article is obtained.

Abstract: A method and an apparatus for stabilizing the position of a sheet-like element made of hard brittle material during transportation thereof along a transport path is provided in which the element is guided through a roller chicane having three rollers.

Abstract: A method for testing the strength of a sheet-like element having two opposite faces and made of hard brittle material under tensile stress is provided. The method includes passing each of the faces of the element over a roller and thereby bending the element so that each of the faces is subjected to a first tensile stress in a portion in which the opposite face is in contact with a surface of the roller; exerting a second tensile force on the element in the direction of advancement so that both faces are subjected to the second tensile stress of at least 2 MPa so that the first and second tensile stresses add up to define a resultant tensile stress; and monitoring the element and determining whether the element has a defined breaking strength equal to the resultant tensile stress or whether the element breaks under the resultant tensile stress.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: The disclosure relates to a method for producing, without a mold, a shaped glass article having a predefined geometry.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: In a substrate, particularly in a substrate for a mirror support, in which recesses are introduced in one surface, preferably in the back side of the substrate, as a result of which, in particular, bridging pieces are defined between the recesses, in order to achieve the situation that despite a reduced weight, a high rigidity still remains, which means only a slight sagging after its correct uptake in a holding device provided for it, it is provided that at least one first portion of the bridging pieces has a width that is different than a second portion of the bridging pieces.

Abstract: In a substrate, particularly in a substrate for a mirror support, in which recesses are introduced in one surface, preferably in the back side of the substrate, as a result of which, in particular, bridging pieces are defined between the recesses, in order to achieve the situation that despite a reduced weight, a high rigidity still remains, which means only a slight sagging after its correct uptake in a holding device provided for it, it is provided that at least one first portion of the bridging pieces has a width that is different than a second portion of the bridging pieces.

Abstract: A monolithic substrate of glass or glass ceramics and methods for manufacturing are provided, where the substrate has a lightweight structure. The lightweight structure includes recesses that are delimited by webs, such webs forming tetragonal or four-corner-shaped pockets. Due to the lightweight structure, the weight of the substrate can be significantly reduced, and at the same time a high rigidity can be ensured. The substrate can be used as a mirror support or a mirror and can be employed terrestrially and/or extra-terrestrially.

Abstract: The invention concerns a method for separating plate-shaped workpieces of mechanically brittle and nonmetal materials along any contour desired, comprising the following steps: Scratching of separating lines along the contour up to a depth T by means of a cutting device in at least one side of the plate-shaped workpiece is hereby characterized in that the plate-shaped workpiece is stimulated to bending vibrations at a vibration amplitude along the separating lines, so that the plate-shaped workpiece is completely separated along the separating line.